

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: William Gaarde and Andrew T. Watt

For: **Antisense Modulation of Connective Tissue
Growth Factor Expression**

BOX SEQUENCE

Assistant Commissioner for Patents
Washington DC 20231

DATE OF DEPOSIT: 11/29/01
 I HEREBY CERTIFY THAT THIS PAPER IS BEING
 DEPOSITED WITH THE UNITED STATES POSTAL
 SERVICE AS FIRST CLASS MAIL, POSTAGE
 PREPAID ON THE DATE INDICATED ABOVE AND
 IS ADDRESSED TO THE ASSISTANT
 COMMISSIONER FOR PATENTS, WASHINGTON, DC
 20231.

TYPED NAME: Donna T. Ward
 REGISTRATION NO.: 48,271

PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find the following:

- The specification of the above-referenced patent application;
- An **executed** Declaration or Oath and Power of Attorney;
- An Assignment of the invention to **Isis Pharmaceuticals Inc.** with recordation cover sheet (PTO Form PTO-1595) and \$40.00 cover fee;
- Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR § § 1.821 through 1.825;
- Sequence listing in computer readable form in accordance with 37 C.F.R. § 1.821(e);
- An Information Disclosure Statement with references; and
- Applicant claims small entity status pursuant to 37 CFR § 1.27; and
- Statement of attempt to deposit correspondence with the USPS via Express Mail.

The filing fee has been calculated as shown below:

For:	No. Filed	No. Extra	Rate	Fee
BASE FEE				\$370.00
Total Claims	20 - 20 =	0	X \$9=	\$0
Indep. Claims	2 - 3 =	0	x\$40=	\$0
TOTAL				\$ 370.00

The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 500252:

- the amount of \$410.00 for the above listed fees;
- payment of the following fees associated with this communication or credit any overpayment;
- any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims; and
- any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20 (d).

Triplicate copies of this transmittal are enclosed.

Date: November 29, 2001

Donna T. Ward
 Donna T. Ward
 Registration No. 48,271
 Isis Pharmaceuticals, Inc.

Please address all correspondence to:
 Jane Massey Licata or Kathleen A. Tyrrell
 Licata & Tyrrell, P.C.
 66 East Main Street
 Marlton NJ 08053
 (856) 810-1515

to offer.

This statement should not be construed as a representation that an exhaustive search has been made, or that information more material to the examination of the present application does not exist. The Examiner is specifically requested not to rely solely on the materials submitted herewith. The Examiner is requested to conduct an independent and thorough review of the documents, and to form independent opinions as to their significance.

It is requested that the information disclosed herein be made of record in this application and that the Examiner initial and return a copy of the enclosed PTO-1449 to indicate the documents have been considered.

Respectfully Submitted,

**THOMAS, KAYDEN, HORSTEMEYER
& RISLEY, L.L.P.**

By: 
Adam E. Crall, Reg. No. 46,646

100 Galleria Parkway, Suite 1750
Atlanta, Georgia 30339-5948
770-933-9500

CERTIFIED MAILING

I hereby certify that this correspondence is being deposited
with the United States Postal Service as "First Class Mail,"
in an envelope addressed to: Assistant Commissioner of
Patents and Trademarks, Washington, D.C.

20231 on 10-30-01


Signature

11/29/2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): William Gaarde and Andrew T. Watt

Serial No.: not yet assigned Filing Date: herewith

Title: Antisense Modulation of Connective Tissue Growth Factor Expression


Statement of attempt to deposit correspondence with the USPS via Express Mail.

Date of attempt to deposit via Express Mail: 11/29/01

I hereby certify that I attempted to deposit this correspondence with the USPS via Express Mail on the above date. The USPS refused to accept this correspondence on said date.


Typed Name: Pamela Grooms

I hereby certify that all statements made herein are true.


Donna T. Ward

Registration No.: 48,271

Date: November 29, 2001

Please address all correspondence to:
Jane Massey Licata or Kathleen A. Tyrrell
Licata & Tyrrell, P.C.
66 East Main Street
Marlton NJ 08053
(856) 810-1515

DOCKET NO.: RTS-0274

Date of Deposit: 11/29/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): William Gaarde and Andrew T. Watt

Serial No.: not yet assigned Filing Date: herewith

Title: Antisense Modulation of Connective Tissue Growth Factor Expression

BOX SEQUENCE

Assistant Commissioner for Patents


Washington, D.C., 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§
1.821 THROUGH 1.825

I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

Date: November 29, 2001

Respectfully submitted,


Donna T. Ward
Registration No. 48,271
Isis Pharmaceuticals, Inc.

Please address all correspondence to:

Licata & Tyrrell, P.C.
66 East Main Street
Marlton NJ 08053
(856) 810-1515

10005191-120001